news
Forecasting in dynamic Oncology Markets
14 March 2016 | By Black Swan Analysis
Two big things struck me as interesting during an Innovations in Oncology Conference in Edinburgh this month...
List view / Grid view
Oncology
news
Lenvatinib approved in Israel for patients with advanced thyroid cancer
9 March 2016 | By Victoria White
From today, people in Israel with radioactive iodine refractory differentiated thyroid cancer will have access to Eisai’s Lenvima (lenvatinib)...
news
Aprea closes EUR 46 million Series B financing round
9 March 2016 | By Victoria White
Aprea says the funds will be used to advance the clinical development of its lead programme APR-246, a first-in-class anticancer compound reactivating the tumour suppressor protein p53...
news
Researchers make cancer immunotherapy ‘breakthrough’
4 March 2016 | By Victoria White
Researchers have found the tools necessary to give immunotherapy the precision guidance that patients with cancer so desperately need...
article
Directing a weaponised attack on cancer with Natural Killer Receptor T-Cells
Natural killer receptor T-cells have the potential to become a real game changing treatment for patients with cancer. Here, Dr Frédéric Lehmann, VP Immuno-Oncology, Celyad, discusses this new cancer fighting technology...
news
‘Extraordinary’ t-cell therapy results could change the face of cancer treatment
16 February 2016 | By Victoria White
In one study, the engineered T-cells induced complete remission in 94% of patients with acute lymphoblastic leukaemia...
news
Results from eribulin study in liposarcomas and leiomyosarcomas published
11 February 2016 | By Victoria White
Eisai's Halaven (eribulin) is the first in the halichondrin class of microtubule dynamics inhibitors with a novel mechanism of action...
news
Breakthrough Therapy designation for Adaptimmune’s NY-ESO-1-T cell therapy
10 February 2016 | By Victoria White
The Breakthrough Therapy designation was based on the results of a Phase I/II trial in patients with unresectable, metastatic or recurrent synovial sarcoma...
news
RedHill Biopharma and IZI enter RP101 collaboration
8 February 2016 | By Victoria White
The research collaboration will test RP101 in preclinical oncology models in combination with standard-of-care chemotherapies to support existing Phase I and Phase II clinical data...
news
Head and neck cancer treatment market to reach $1.53b by 2024
3 February 2016 | By Victoria White
GlobalData says the treatment market for head and neck cancer will expand almost fourfold from $386 million in 2014 to $1.53 billion...
news
Targovax submits study protocol for ONCOS-102 to Spanish authorities
2 February 2016 | By Victoria White
Targovax has submitted a study protocol to the regulatory authorities in Spain to assess ONCOS-102 in patients with malignant pleural mesothelioma...
news
STRIVE results for enzalutamide in CRPC published
27 January 2016 | By Victoria White
The study achieved its primary endpoint demonstrating a statistically significant increase in PFS for enzalutamide compared with bicalutamide...
news
Vectibix and best supportive care improves OS in mCRC
25 January 2016 | By Victoria White
Amgen has announced results from a study of Vectibix and best supportive care in patients with chemorefractory wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC)...
news
EC approves Type II variation for Takeda’s Adcetris
22 January 2016 | By Victoria White
The EC has approved the Type II variation for Adcetris to include data on the retreatment of adult patients with R/R Hodgkin lymphoma or R/R sALCL who previously responded to Adcetris and who later relapse....
news
DelMar teams up with MD Anderson for VAL-083 trial in GBM
14 January 2016 | By Victoria White
VAL-083 is a first-in-class small molecule chemotherapy that readily crosses the blood brain barrier...
